A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Joseph Mikhael; Karim Belhadj-Merzoug; Cyrille Hulin; Laure Vincent; Philippe Moreau; Cristina Gasparetto; Ludek Pour; Ivan Spicka; Ravi Vij; Jeffrey Zonder; Djordje Atanackovic; Nashat Gabrail; Thomas G. Martin; Aurore Perrot; Samira Bensfia; Qilong Weng; Claire Brillac; Dorothée Semiond; Sandrine Macé; Kathryn P. Corzo; Xavier Leleu

doi:10.1038/s41408-021-00478-4

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, Ivan Spicka, Ravi Vij, Jeffrey Zonder, Djordje Atanackovic, Nashat Gabrail, Thomas G. Martin, Aurore Perrot, Samira Bensfia, Qilong Weng, Claire Brillac, Dorothée Semiond, Sandrine Macé, Kathryn P. CorzoXavier Leleu

Research output: Contribution to journal › Letter › peer-review

32 Scopus citations

Original language	English
Article number	89
Journal	Blood cancer journal
Volume	11
Issue number	5
DOIs	https://doi.org/10.1038/s41408-021-00478-4
State	Published - May 2021

Access to Document

10.1038/s41408-021-00478-4

Cite this

Mikhael, J., Belhadj-Merzoug, K., Hulin, C., Vincent, L., Moreau, P., Gasparetto, C., Pour, L., Spicka, I., Vij, R., Zonder, J., Atanackovic, D., Gabrail, N., Martin, T. G., Perrot, A., Bensfia, S., Weng, Q., Brillac, C., Semiond, D., Macé, S., ... Leleu, X. (2021). A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood cancer journal, 11(5), [89]. https://doi.org/10.1038/s41408-021-00478-4

@article{2347612e90c943eb8aa84b601e29bac6,

title = "A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab",

author = "Joseph Mikhael and Karim Belhadj-Merzoug and Cyrille Hulin and Laure Vincent and Philippe Moreau and Cristina Gasparetto and Ludek Pour and Ivan Spicka and Ravi Vij and Jeffrey Zonder and Djordje Atanackovic and Nashat Gabrail and Martin, {Thomas G.} and Aurore Perrot and Samira Bensfia and Qilong Weng and Claire Brillac and Doroth{\'e}e Semiond and Sandrine Mac{\'e} and Corzo, {Kathryn P.} and Xavier Leleu",

note = "Funding Information: The study was sponsored by Sanofi. The authors thank the participating patients and their families, and the study centers and investigators, for their contributions to the study. Medical writing support was provided by Camile Semighini Grubor, PhD, of Elevate Medical Affairs, contracted by Sanofi Genzyme for publication support services.",

year = "2021",

month = may,

doi = "10.1038/s41408-021-00478-4",

language = "English",

volume = "11",

journal = "Blood Cancer Journal",

issn = "2044-5385",

number = "5",

}

Mikhael, J, Belhadj-Merzoug, K, Hulin, C, Vincent, L, Moreau, P, Gasparetto, C, Pour, L, Spicka, I, Vij, R, Zonder, J, Atanackovic, D, Gabrail, N, Martin, TG, Perrot, A, Bensfia, S, Weng, Q, Brillac, C, Semiond, D, Macé, S, Corzo, KP & Leleu, X 2021, 'A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab', Blood cancer journal, vol. 11, no. 5, 89. https://doi.org/10.1038/s41408-021-00478-4

TY - JOUR

T1 - A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

AU - Mikhael, Joseph

AU - Belhadj-Merzoug, Karim

AU - Hulin, Cyrille

AU - Vincent, Laure

AU - Moreau, Philippe

AU - Gasparetto, Cristina

AU - Pour, Ludek

AU - Spicka, Ivan

AU - Vij, Ravi

AU - Zonder, Jeffrey

AU - Atanackovic, Djordje

AU - Gabrail, Nashat

AU - Martin, Thomas G.

AU - Perrot, Aurore

AU - Bensfia, Samira

AU - Weng, Qilong

AU - Brillac, Claire

AU - Semiond, Dorothée

AU - Macé, Sandrine

AU - Corzo, Kathryn P.

AU - Leleu, Xavier

N1 - Funding Information: The study was sponsored by Sanofi. The authors thank the participating patients and their families, and the study centers and investigators, for their contributions to the study. Medical writing support was provided by Camile Semighini Grubor, PhD, of Elevate Medical Affairs, contracted by Sanofi Genzyme for publication support services.

PY - 2021/5

Y1 - 2021/5

UR - http://www.scopus.com/inward/record.url?scp=85105788793&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00478-4

DO - 10.1038/s41408-021-00478-4

M3 - Letter

C2 - 33980831

AN - SCOPUS:85105788793

SN - 2044-5385

VL - 11

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 5

M1 - 89

ER -

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Access to Document

Other files and links

Cite this